REG - GSK Capital B.V. - Annual Financial Report

GSKAnnouncement

03/06/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240603:nRSC9222Qa&default-theme=true

RNS Number : 9222Q  GSK Capital B.V.  03 June 2024

Publication of GSK Capital BV's

 

Annual Report & Financial Statements 2023

 

 

Today, 3 June 2024, GSK Capital B.V. (the "Company") published on the GSK
Group ("GSK") website, www.gsk.com*, its Annual Report and Financial
Statements in respect of the year ended 31 December 2023.

 

In compliance with Listing Rule 9.6.1 of the UK Financial Conduct Authority
("FCA"), copies of the Company's 2023 Annual Report and Financial
Statements, have been submitted to the FCA's National Storage Mechanism
(NSM) submission portal via Electronic Submission System (ESS). The Company is
using the exemption available to it under the Disclosure and Transparency
Rules 6.3.5(1A) and is not setting out the full text of the regulated
information in this announcement and has instead made the regulated
information available in unedited full text on the NSM.

A copy can be viewed at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

 

V A Whyte

GSK plc Company Secretary

3 June 2024

 

 *
https://www.gsk.com/en-gb/company/codes-standards-and-reports/#gsk-capital-plc-annual-reports

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q1 Results for 2024.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSEASKDEFLLEFA